In vitro investigations of FAK inhibition in combination with Tamoxifen, Lapatinib, and Paclitaxel, in ER+, Her2+, and triple negative breast cancers respectively, demonstrated additional reductions in CSC activity (primary mammosphere formation) with Lapatinib and Paclitaxel. Here, ERBB2 is linked to triple-negative breast carcinoma.